(Health Korea News / Lee Chang-yong) The Korea Pharmaceutical and Bio-Pharma Association, together with the Korea Innovative Pharmaceutical Consortium, held a ‘Vietnam Market Entry Briefing Session: Clinical Field’ at Novotel Ambassador Seoul Gangnam on the 4th.
The briefing session consisted of ▲Introduction of Vietnam’s clinical policy (Vietnam Ministry of Health) ▲Exploration of Vietnam’s clinical trials (Haiphong University of Medicine and Pharmacy) ▲Development of Vietnam’s clinical research (Bigleap) ▲Things to consider when domestic companies enter Vietnam (Aimedisurvey) ▲Sharing of cases of domestic companies entering Vietnam (Daewon Pharmaceutical).
At the briefing session, the Science, Technology and Training Administration (ASTT) under the Ministry of Health of Vietnam directly explained Vietnam’s clinical trial policy, including the clinical fields that Vietnam is currently focusing on and future policy directions. Hai Phong University of Medicine and Pharmaceutical Sciences introduced the clinical trial process in Vietnam through its own clinical trial case, as well as the infrastructure and quality management system of the ‘Clinical Trials and Bioequivalence Research Center’ within the university.
The representative of Bigleap, one of the leading CROs in Vietnam, presented the Vietnamese clinical research environment, regulations, clinical trial duration, and benefits. Kim Dong-chul, the representative of Aimedisurvey, which specializes in Korean-Vietnamese pharmaceutical consulting, shared important points for domestic companies looking to enter the Vietnamese market.
Daewon Pharmaceutical introduced the current status of its entry into the Vietnamese market through improved new drugs and provided information that domestic companies should consider when conducting clinical trials in Vietnam.
Lee Hyun-woo, executive director of the Korea Pharmaceutical and Bio-Pharmaceutical Association, said, “Vietnam is considered a bridgehead for entering ASEAN, but it is also a difficult market in terms of clinical trials and licensing. I hope that this briefing session will help domestic pharmaceutical and bio companies prepare strategies for entering Vietnam clinical trials and the market,” and “The association will continue to make efforts to help domestic companies successfully settle into global expansion, including ASEAN.”
This event, which was organized to provide insight into domestic pharmaceutical and biotech companies entering the Vietnamese pharmaceutical market, was attended by approximately 100 people from the domestic pharmaceutical and biotech industry.
Copyright © Health Korea News. Unauthorized reproduction and redistribution prohibited.
Source: www.hkn24.com
